SUNNYVALE, Calif. (PRWEB) September 05, 2013
Freeslate, Inc., the leading provider of high throughput research solutions, today announced the launch of its CM Protégé Bioformulation Assessment System designed to streamline the assessment of biologic formulation stability. The product eliminates critical analytical bottlenecks by automating visible particle detection, pH measurements, and viscosity measurements. It will be highlighted in the company’s booth (Booth #727) during the BioProcess International Conference, September 16-19, 2013 in Boston, Massachusetts.
Previously, the measurement of visible particles, viscosity, and pH was time-consuming and labor intensive, requiring manual measurement on separate instruments. The CM Protégé Bioformulation Assessment System both automates and accelerates these analyses, completing them in less than two minutes per measurement.
“We continue to bring products to market that address the bottlenecks in developing robust biologics formulations,” said John S. Senaldi, President and CEO of Freeslate. “The introduction of the CM Protégé Bioformulation Assessment System provides more scientists access to these productivity tools that accelerate formulation development.”
Unique to the CM Protégé Bioformulation Assessment System is the Visual Inspection Station, which unlike manual visible inspection, digitally acquires and stores images for post-run processing, creating a permanent record. Freeslate’s Lab Execution and Analysis (LEA) software suite provides an objective and consistent measurement of particle count and eliminates human interpretation and error. Through LEA, the analytical data generated on the System is saved to the Freeslate Database where it can be associated with the sample composition and sample stress conditions.
The development of robust protein and vaccine formulations requires screening and stability studies that evaluate a range of formulation and stress conditions. The CM Protégé Bioformulation Assessment System helps scientists quickly assess the stability of formulations supporting fast project turnaround times. Ultimately the System can help users accelerate the time to Phase I clinical trials, and time to market for biotherapeutics.
Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.